TRPV1 receptor blockade is ineffective in different in vivo models of migraine

Activation of TRPV1 Mediates Calcitonin Gene-Related Peptide Release, Which Excites Trigeminal Sensory Neurons and Is Attenuated by a Retargeted Botulinum Toxin with Anti-Nociceptive Potential

(2009) J. Meng et al.   JOURNAL OF NEUROSCIENCE

The effects of the TRPV1 receptor antagonist SB-705498 on trigeminovascular sensitisation and neurotransmission

(2009) G. A. Lambert et al.   NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY

Transient receptor potential vanilloid type 1 receptor regulates glutamatergic synaptic inputs to the spinothalamic tract neurons of the spinal cord deep dorsal horn

(2009) H. Kim et al.   NEUROSCIENCE

Neurobiology of migraine

(2009) P.J. Goadsby et al.   NEUROSCIENCE

Repeated dosing of ABT-102, a potent and selective TRPV1 antagonist, enhances TRPV1-mediated analgesic activity in rodents, but attenuates antagonist-induced hyperthermia

(2009) Prisca Honore et al.   PAIN

Electrophysiological and morphological properties of neurons in the substantia gelatinosa of the mouse trigeminal subnucleus caudalis

(2009) Alexander J. Davies et al.   PAIN

Antihyperalgesic Effects of (R,E)-N-(2-Hydroxy-2,3-dihydro-1H-inden-4-yl)-3-(2-(piperidin-1-yl)-4-(trifluoromethyl)phenyl)-acrylamide (AMG8562), a Novel Transient Receptor Potential Vanilloid Type 1 Modulator That Does Not Cause Hyperthermia in Rats

(2008) S. G. Lehto et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial

(2008) Tony W Ho et al.   LANCET

Painful toxins acting at TRPV1

(2007) Brett A. Cromer et al.   TOXICON